Essential Science

Oxford, UK & Edzell, UK, 1 Oct 2006 - Prolysis Ltd, a private company focused on the discovery and development of novel antibiotic therapies, and Essential Science Ltd, the technology exploitation company, today announced continued collaboration focused on the commercialisation of Prolysis' novel bacterial cell biology expertise. The agreement concentrates on the exploitation of Prolysis' class-leading antibiotic screening assay technology, which the company plans to make available on a collaborative basis to interested parties.

Essential Science will provide business development support to Prolysis aimed at establishing long-lasting relationships in the areas of library screening, in-licensing of development candidates, out-licensing of Prolysis technologies and development of new applications for Prolysis technology.

About Prolysis

Prolysis has established five proprietary whole cell assays that target critical pathways ensuring that potential therapeutics can enter the bacterial cell. All five assays have been validated with multiple hits and with the advancement of one Prolysis program to lead optimisation stage against a target of significant pharmaceutical interest. Prolysis uses its proprietary high-throughput "dual-reporter" assay system complemented by state-of-the-art fluorescent microscopy for an information-rich understanding of target hits.

www.prolysis.com

About Essential Science

Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.

Enquiries :: Neil Murray :: +44 1356 648941 :: neil@essentialscience.co.uk

Date :: Sunday 01 October 2006